Fondazione IRCCS Istituto Nazionale dei Tumori-ko ikertzaileekin lankidetzan egindako argitalpenak (2)

2020

  1. Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study

    Lung Cancer, Vol. 147, pp. 137-142

2016

  1. Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)

    ESMO Open, Vol. 1, Núm. 6